15th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV

96 Pages·2013·1.15 MB·English

Abstracts presented at the
15th International Workshop on Co-morbidities
and Adverse Drug Reactions in HIV
Brussels, Belgium, 15–17 October 2013
Lipo_Prelims_2013.indd 1 18/10/2013 16:36:22
ORGANIZING COMMITTEE
Chairs for 2013
Stefan Mauss Center for HIV and Hepatogastroenterology, Düsseldorf, Germany
Kathleen Mulligan University of California at San Francisco, CA, USA
Peter Reiss Academic Medical Center, Amsterdam, The Netherlands
Jacqueline Capeau Faculty of Medicine Saint Antoine, INSERM, Paris, France
Andrew Carr St Vincent’s Hospital, Sydney, Australia
David Cooper University of New South Wales, Sydney, Australia
Morris Schambelan University of California at San Francisco, CA, USA
Ian Weller University College London Medical School, London, UK
SCIENTIFIC COMMITTEE
Todd Brown Johns Hopkins University, Baltimore, MD, USA
Judith Currier University of California, Los Angeles, CA, USA
Michael Dubé University of Southern California, Los Angeles, CA, USA
Julian Falutz Immune Deficiency Treatment Center, Montreal General Hospital,
Montreal, Canada
Steve Grinspoon Massachusetts General Hospital, Boston, MA, USA
Carl Grunfeld University of California Medical Center, San Francisco, CA, USA
Giovanni Guaraldi University of Modena, Modena, Italy
Donald Kotler Columbia University, New York, NY, USA
Jules Levin The National AIDS Treatment Advocacy Project, New York, NY, USA
Jens Lundgren University of Copenhagen, Hvidovre, Denmark
Esteban Martínez IDIPAPS - Hospital Clinic, University of Barcelona, Barcelona, Spain
Graeme Moyle Chelsea and Westminster Hospital, London, UK
Willy Rozenbaum Hôpital Tenon, Université Pierre et Marie Curie, Paris, France
Pablo Tebas University of Pennsylvania, Philadelphia, PA, USA
Sharon Walmsley University Health Network, Toronto, Canada
Kevin Yarasheski Washington University, St Louis, MO, USA

PLENARY SPEAKERS
Claudio Franceschi University of Bologna, Bologna, Italy
Scott Kinlay Brigham and Women’s Hospital, Boston, MA, USA
Patrick Mallon University College Dublin, Dublin, Ireland
Fergus Shanahan University College Cork, Cork, Ireland
Simon Thomas Newcastle University, Newcastle, UK
Heiner Wedemeyer Hannover Medical School, Hannover, Germany
ORGANIZING SECRETARIAT
International Medical Press Admiral House
76–78 Old Street
London, EC1V 9AZ, UK
Tel: [phone]
Fax: [phone]
www.intmedpress.com/comorbidities
[email protected]
ii Programme & Abstracts
Lipo_Prelims_2013.indd 2 18/10/2013 16:36:22
ABSTRACT CONTENTS
PAGE TITLE AND PRESENTING AUTHOR ABSTRACT
ORAL PRESENTATIONS
Session 1
A3 Vitamin D level in HIV-infected persons: prognostic value for all-cause O01
death, and association with inflammatory markers, results from the
EuroSIDA cohort study
JP Viard
A3 Tryptophan metabolism and its relationship with immune activation, O02
depression, and neurocognitive impairment among HIV-infected
individuals
MR Keegan
A4 The effect of antiretroviral penetration into the central nervous system O03
on the incidence of AIDS-defining neurological conditions in a
prospective observational study
EC Caniglia
A5 Lopinavir associated with ritonavir induces premature senescence and O04
calcification of vascular smooth muscle cells in vitro
P Afonso
Session 2
A6 Decreases in cholesterol in HIV-seronegative men using emtricitabine/ O05
tenofovir pre-exposure prophylaxis: lipid results of iPrEx
K Mulligan
A7 STaR study: single-tablet regimen rilpivirine/emtricitabine/tenofovir DF O06
maintains non-inferiority to efavirenz/emtricitabine/tenofovir DF
and has minimal impact on fasting lipids in ART-naive adults through
week 96
C Cohen
A8 Darunavir, atazanavir and lopinavir boosted by ritonavir differentially O07
affect endothelial functions and induce senescence of cultured human
endothelial cells: beneficial effect of pravastatin
J Capeau
A8 Effects of antiretroviral therapy initiation on soluble CD163 and O08
asymmetric dimethyl arginine levels and their relationships with
endothelial function: results from a 24-week prospective randomized trial
MP Dubé
Session 3
A9 Most recent, mean and median viral load predict myocardial infarction (MI) O09
H Crane
A10 Plasma plasminogen activator inhibitor-1 predicts first-time myocardial O10
infarction in HIV-infected individuals
A Knudsen
15th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV iii
Lipo_Prelims_2013.indd 3 18/10/2013 16:36:22
PAGE TITLE AND PRESENTING AUTHOR ABSTRACT
A10 Association of epicardial adipose tissue with incident coronary heart O11
disease and death in HIV-infected patients
G Guaraldi
A11 Management of cardiovascular risk in HIV-positive individuals in Europe O12
M Shahmanesh
Session 4
A12 STARTVerso 4 Phase III trial of faldaprevir once-daily plus peg interferon O13
alfa-2a and ribavirin (PR) in patients with HIV and HCV genotype 1
coinfection: end of treatment response (ETR)
M Manero
A13 Triple therapy with telaprevir (TPV) or boceprevir (BOC) in cirrhotic O14
HIV/HCV-infected patients: real-life on-treatment data from Europe
D Salmon
A13 Efficacy of DAAs-based HCV triple therapy in HIV–HCV-coinfected O15
patients: interim 24-week results
S Mauss
A14 Anti-fibrotic and anti-inflammatory activity of the dual CCR5 and CCR2 O16
antagonist cenicriviroc in a mouse model of NASH
E Lefebvre
Session 5
A15 Changes in bone turnover markers and association with decreased O17
total bone mineral density (tBMD) in treatment-naive subjects taking
lopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine
TT Brown
A15 Reduced bone mineral density (BMD) is largely explained by lower body O18
weight in HIV-positive individuals and more pronounced in younger men
having sex with men (MSM), regardless of HIV status
KW Kooij
A17 Association of osteoporosis and sarcopenia in treated HIV patients O19
J Falutz
A17 Lean mass (LM) has a greater effect on bone mineral density (BMD) than O20
fat mass (FM): data from a cohort of HIV-positive and HIV-negative
subjects
AG Cotter
Session 6
A18 Serious clinical outcomes are under-reported in prospective studies of O21
initial antiretroviral therapy in HIV-1-infected adults
FJ Lee
A19 Haemoglobin A1c is a poor predictor of fasting glycaemia in HIV-infected O22
men with low CD4 count, high mean corpuscular haemoglobin and red
cell volume
L Slama
A19 Reversibility of estimated glomerular filtration rate (eGFR) in O23
HIV-infected patients discontinuing tenofovir: the Swiss HIV Cohort
Study (SHCS)
HC Bucher
iv Programme & Abstracts
Lipo_Prelims_2013.indd 4 18/10/2013 16:36:22
PAGE TITLE AND PRESENTING AUTHOR ABSTRACT
A20 High prevalence of anal human papilloma virus infection and related cancer O24
precursors in a contemporary cohort of asymptomatic HIV-infected women
I Heard
Joint session with 14th European AIDS Conference
A21 Acute kidney injury caused by tenofovir disoproxil fumarate and diclofenac O25
co-administration
M Bickel
A21 Greater arterial stiffness in middle-aged HIV-positive men on cART may O26
be explained by an increased prevalence of hypertension, smoking and
systemic inflammation
KW Kooij
A23 An updated prediction model of the global risk of cardiovascular disease O27
in HIV-positive persons; the Data-collection on Adverse Effects of
Anti-HIV Drugs (D:A:D) Study
N Friis-Møller
A24 Low bone mineral density is associated with increased risk of incident O28
fracture in HIV-infected adults
L Battalora
POSTER PRESENTATIONS
Aging & associated disorders
A27 Longitudinal leukocyte telomere length during pregnancy and P01
post-partum in HIV+ women on combination antiretroviral therapy
compared to HIV- pregnant women
HCF Côté
A27 Predictive accuracy of VACS index for all-cause mortality in HIV-infected P02
people enrolled in a large cohort in Italy
L Gazzola
A28 Immune activation analysis over 48 weeks in INROADS, a study of the P03
nucleoside/tide-sparing regimen of once-daily etravirine and
darunavir/ritonavir
ET Overton
Body composition
A31 An empirically validated responder definition for the reduction of visceral P04
adipose tissue (VAT) in HIV-infected patients with lipodystrophy
A Mangili
Bone metabolism & toxicities
A33 Human osteoblast CXCR4 expression is upregulated by HIV gp120 P05
NSY Chew
A33 Reduced high density lipoprotein cholesterol (HDLc) rather than elevated P06
low density lipoprotein (LDLc) is the principal dyslipidaemia in
HIV-positive subjects on contemporary antiretroviral therapy (ART)
AG Cotter
A34 No significant differences between non-traumatic bone fractures P07
hospitalization’s prevalence between HIV and non-HIV populations
in the last 24 years
P Freitas
15th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV v
Lipo_Prelims_2013.indd 5 18/10/2013 16:36:22
PAGE TITLE AND PRESENTING AUTHOR ABSTRACT
A35 What is the prevalence of low bone mineral density of men ≥50 years P08
living with HIV under treatment in a general Dutch Hospital and can the
fracture risk score of the CBO be of use to determine patients at risk of
osteoporosis?
C Meerkerk
A85 Low-dose oral vitamin D and calcium replacement may prevent loss P65
of bone mineral density in HIV patients: a non-randomized open-label
single-centre trial
H Taha
Cancer in patients with HIV/AIDS
A37 HIV screening of patients with AIDS-defining cancers: a 10-year P09
retrospective analysis of practices in a Swiss university hospital
KEA Darling
A37 High-grade squamous intraepithelial lesions (HSIL) detected during anal P10
cancer screening in HIV-infected patients in routine practice
O Faucher
A38 High prevalence of anal dysplasia in a cohort of HIV-positive MSM enrolled P11
in a systematic screening programme: risk factors and impact of cART
A Libois
A39 Prevalence of anal intraepithelial neoplasia among HIV-positive Mexican P12
men who have sex with men
JA Mata-Marín
Cardiovascular disease
A41 Carotid intima-media thickness assessment in high cardiovascular risk P13
HIV-infected patients randomized to an intensive intervention on
lifestyle versus routine care
S Di Yacovo
A41 B-type natriuretic peptide elevation is more frequent in HIV+ patients P14
compared to the general population
B Schwarz
A42 Left ventricular diastolic dysfunction is associated with insulinoresistance P15
factors in HIV-infected patients under antiretroviral therapy
A Fonteille
A43 Cerebro and cardiovascular mortality increased 2 and 5 times, respectively, P16
in the last 24 years in HIV populations: a hospital-based study
P Freitas
A43 Emphysema is an independent predictor of coronary artery calcium score P17
in a large cohort of HIV-infected patients
G Guaraldi
A44 Prevalence and predictors of preclinical coronary heart disease in P18
post-menopause period
G Guaraldi
A45 Morbidity and mortality of HIV-infected individuals with cardiovascular P19
risk factors in Hong Kong
GCY Lui
vi Programme & Abstracts
Lipo_Prelims_2013.indd 6 18/10/2013 16:36:22
PAGE TITLE AND PRESENTING AUTHOR ABSTRACT
A45 Cardiovascular risk factor in HIV Mexican population on antiretroviral P20
therapy
JA Mata-Marín
A46 3 Years of cardiovascular (CV) risk monitoring in an inner city HIV cohort P21
M Pakianathan
A46 Cardiovascular risk estimated by carotid Doppler in HIV compared with P22
nadir CD4 and time of diagnosis of HIV infection
P Ruiz
A47 Decreased trunk fat and triglycerides after strength training are P23
associated with reduced LPS levels in HIV-infected individuals
M Trøseid
A47 Plasma LPS and triglycerides are intercorrelated and associated with P24
development of the metabolic syndrome in HIV infection
M Trøseid
A48 Evidence of premature atherosclerosis in HIV-infected individuals P25
with low cardiovascular disease risk factors on carotid magnetic
resonance imaging
JH Vera
A48 Structural and functional arterial parameters, immunovirological P26
control and vitamin D in HIV-infected patients
D Agnoletti
Clinical management of ADRs
A51 Sequencing antiretroviral therapy to maximize patient safety: could we P27
move away from ritonavir, abacavir, tenofovir and efavirenz (RATE) –
agents that concern prescribers and patients? A feasibility study and call
for a trial
AC Achhra
A52 DRESS syndrome related to raltegravir P28
M Beato Prata
A52 Chronic diarrhoea in HIV-infected patients P29
JR Blanco
A53 Switching ART-controlled HIV-infected patients to maraviroc plus P30
raltegravir dual therapy results in changes in fat, metabolic parameters
and circulating immune activation markers: results from the ROCnRAL
ANRS 157 study
J Capeau
A53 ABSTRACT WITHDRAWN P31

Co-morbidity pathogenesis
A55 Brain imaging and CSF findings in patients with HIV and neurological P32
symptoms
O Davies
15th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV vii
Lipo_Prelims_2013.indd 7 18/10/2013 16:36:22
PAGE TITLE AND PRESENTING AUTHOR ABSTRACT
A56 Risk factors for osteoporosis in HIV patients aged 50 years or more P33
S De Wit
A56 Calcaneal stiffness index to screen for osteoporosis in HIV patients: a P34
valuable tool?
S De Wit
A57 Is the impact of statins on overall mortality different in HIV-infected P35
individuals compared to the general population? Results from
FHDH-ANRS CO4
S Lang
A58 Effect of two first-line ART regimens on various inflammatory markers in P36
HIV patients: a new criterion in selecting antiretrovirals?
VD Papakonstantinou
A58 Amino acid concentrations in HIV-infected youth compared to healthy P37
controls and associations with CD4 counts and inflammation
A Ross Eckard
A59 Trace element levels are linked to CD4 counts and HIV-1 RNA in a cohort P38
of inner-city HIV+ patients admitted with respiratory symptoms
A Ross Eckard
Hepatitis
A61 Safety and efficacy of rilpivirine-tenofovir-emtricitabine (Eviplera®) in P39
hepatitis C–HIV coinfection
A Gothard
A62 Does the choice of antiretroviral class matter in HIV/HCV-coinfected P40
patients treated for chronic hepatitis C?
S Mauss
A62 HCV–HIV coinfection in the French Dat’AIDS cohort at the beginning of P41
HCV direct acting agents (DAAs) era
I Poizot-Martin
A63 Reports of viral hepatitis B and C in HIV patients participating in clinical P42
trials of elvitegravir/cobicistat/tenofovir DF/emtricitabine and cobicistat-
boosted atazanavir plus tenofovir DF/emtricitabine
E Quirk
Insulin resistance
A65 Correlation between fructosamine and haemoglobin A1c in HIV-infected P43
adults
H Crane
Lipid metabolism
A67 ABSTRACT WITHDRAWN P44

A67 The distribution of apolipoprotein E gene polymorphism and their P45
influences in dyslipidemias in HIV-1 infections
C Sukasem
viii Programme & Abstracts
Lipo_Prelims_2013.indd 8 18/10/2013 16:36:22
PAGE TITLE AND PRESENTING AUTHOR ABSTRACT
Liver disease & hepatotoxicity
A69 Maraviroc, a CCR5 antagonist, prevents the development of hepatic P46
steatosis in a mouse model of non-alcoholic fatty liver disease (NAFLD)
JR Blanco
A69 HIV-related pancreatitis significantly increased after cART introduction P47
P Freitas
A70 Risk of liver enzyme elevation during treatment with ritonavir-boosted protease P48
inhibitors among HIV-monoinfected and HIV/HCV-coinfected patients
G Lapadula
Neurocognitive disorders
A73 Neuronal bioenergetics and acute mitochondrial dysfunction: a clue to P49
understanding the CNS side effects of efavirenz?
JV Esplugues
A73 Overestimation of neurocognitive impairment in HIV-infected patients? P50
O Faucher
A74 Amyloid and tau cerebrospinal fluid (CSF) biomarker levels in patients with P51
HIV-associated neurocognitive disorder (HAND) compared to levels in
HIV-negative (HIV-) patients
M Harris
A75 Vitamin D deficiency is associated with higher risk of neurocognitive P52
impairment (NCI) in HIV-infected persons
R Libertone
A76 Cardiovascular disease Framingham risk score (FRS) and VACS index are P53
associated with neurocognitive impairment (NCI) in HIV-positive patients
C Pinnetti
A77 Utilization of psychotropic drugs prescribed to persons with and without P54
HIV infection: a Danish nationwide population-based cohort study
LD Rasmussen
A77 Psychotropic drugs are prescribed more frequently in HIV-positive patients P55
compared to the general population. Data from two German prospective
cohorts: Heinz Nixdorf Recall Study and HIV HEART Study
B Schwarz
A78 Memory impairment in patients living with HIV: the importance of a P56
multidisciplinary approach
C Symeon
Renal toxicities
A79 Renal safety of atazanavir-based regimens in HIV-infected patients P57
J Griffin
A79 Is glomerular filtration rate related to vascular lesions in HIV patients? P58
C Isnard Bagnis
A80 How to estimate glomerular filtration rate in HIV patients? P59
C Isnard Bagnis
A80 Changes in kidney and immunologic function associated to tenofovir P60
exposure and ABCC gene variants
K Maciejewska
15th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV ix
Lipo_Prelims_2013.indd 9 18/10/2013 16:36:22
PAGE TITLE AND PRESENTING AUTHOR ABSTRACT
A81 Tubular dysfunction in HIV-infected patients on antiretroviral therapy P61
in an HIV clinic in Mexico
JA Mata-Marín
A81 Prevalence of proteinuria and KDIGO classification among HIV-positive P62
patients in a tertiary care hospital in Mexico
JA Mata-Marín
A82 Risk factors for proteinuria in HIV-infected patients on antiretroviral P63
therapy
YS Pérez-González
A82 Renal biopsy findings of a cohort of HIV-infected patients P64
J Pires
x Programme & Abstracts
Lipo_Prelims_2013.indd 10 18/10/2013 16:36:22